New technologies include the first data from Xenium In Situ’s future analysis platform
PLIZANTON, CA.,, February 22, 2022 / PRNewswire / – 10x genomics, Inc. (Nasdaq: TXG), a life science leader focused on mastering biology to improve human health, today at its second annual virtual event Xperience 2022 presented new details about future products and capabilities on its single-cell, spatial and in situ platforms. . Highlights include a fixed RNA profiling kit that improves sample preparation workflow and adds flexibility for single-cell Chromium experiments; Visium CytAssist to expand the number of fabric samples available for the spatial platform; and the first-ever look at the future Xenium analyzer.
“Everything we do at 10x Genomics is driven by our belief that in the not too distant future most tissue samples will need to be analyzed using the technologies we develop for a single cell, spatial and in situ,” he said. Ben Hindson, co-founder and chief researcher of 10x Genomics. “Our development mechanism has been launched, innovating, implementing and collaborating to make 2022 the most exciting year of product launches in our history. We are more than ready to build on our track record of more than 20 breakthrough technologies when we supply this year’s unprecedented food conveyor. “
For the single-cell platform, Chromium Xperience 2022 introduces several future products designed to make extensive use of single-cell techniques, eliminate bottlenecks and create more value for researchers around the world:
Profiling of fixed chromium RNA – This kit, which combines brand new chemistry and a formaldehyde-fixing chip to preserve the biological state at the collection site, allows you to collect samples in packages for maximum research flexibility. (Launch is scheduled for mid-2022.)
Isolation of chromium nuclei – This simple, scalable product responds to basic customer requests. The kit allows you to isolate the kernels from frozen fabrics, easy to use and does not require expensive tools (launch is scheduled for mid-2022.)
Chromium BEAM – Built on top of an existing 10x immune profile product, BEAM (Bar Antigen Mapping) will enable antigen recognition map by B- or T-cells with high bandwidth, high plexus and high resolution. (Launch is scheduled for late 2022.)
The 5-cell showcase also featured 5 ‘CRISPR, an extension of unicellular immune profiling to make large-scale functional genomics studies faster and easier; and ATAC v2, upgrade the Single Cell ATAC-seq workflow to increase sensitivity while increasing power discoveries and reducing costs. Both are scheduled to launch by mid-year.
Xperience 2022 also demonstrated the breadth of the Visium Spatial Analysis product roadmap with several future technologies aimed at creating more analytes, more samples and more resolution:
Visium gene expression and protein – This analysis will allow researchers to make a microscopic image of a stained area of FFPE tissue and then profile RNA and dozens of proteins simultaneously in the same section with high spatial separation. (Launch is scheduled for mid-2022.)
Visium CytAssist – A compact desktop instrument that transfers analytes from tissue sections on standard slides to Visium slides, CytAssist simplifies sample processing and allows researchers to view and select the best section of FFPE fabric for Visium analysis. (Launch is scheduled for mid-2022.)
Visium HD – Providing a significant separation leap for spatial analysis, the company expects that Visium HD will offer unprecedented views of continuous data transcripts in heterogeneous tissues with single-cell separation. (It is planned to launch closer to the end of 2022.)
Xperience 2022 gave a first look Xenium, the company’s future in situ platform. The company expects Xenium Analyzer to provide targeted information on gene expression in subcellular resolution at high sensitivity and will be a complete in-situ solution: reliable tools, consumables, panels and software. Xenium is being developed as a high-bandwidth platform that can work with large cohorts of entire sections of fabric without requiring a choice of regions of interest. 10x Genomics expects to ship Xenium Analyzer by the end of 2022.
“We plan to hand over the Xenium Analyzer to customers this year, marking the beginning of a revolution in tissue analysis at the most fundamental level with unprecedented scale,” Hindson added. “With our Xenium platform for in situ analysis, RNA and proteins can be measured in cells from where they originated, which are still in native tissue. Our multi-year roadmap will open up this powerful new opportunity and lead to an explosion of new data and understanding to ultimately master biology and improve human health. Until then, we are tirelessly focused on this mission. “
To learn more about the products presented at Xperience 2022, visit
10xgenomics.com/new-products. The event will also take place on February 24 for Asia-Pacific region area, and registration is open at 10xgenomics.com/xperience.
About 10x Genomics
10x Genomics is a technology company dedicated to creating products for the study, understanding and mastery of biology to improve human health. The company’s comprehensive solutions include instruments, consumables and software to analyze biological systems with resolutions and scales appropriate to the complexity of biology. 10x Genomics products have been adopted by researchers around the world, including all 100 of the world’s top research institutes in the Nature rankings in 2020 based on publications and all 20 of the world’s top pharmaceutical companies by 2020 research and development costs and cited in more for 3,300 scientific papers on discoveries ranging from oncology to immunology and neurology. The company’s patent portfolio includes more than 1,300 issued patents and patent applications.
10x Genomics uses documents from the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conferences, public webcasts and social media accounts as a means of disclosing relevant non-public information and for compliance with its disclosure. obligations under the Regulations of the FD.
See original content for multimedia downloads: https://www.prnewswire.com/news-releases/10x-genomics-showcases-robust-innovation-pipeline-at-xperience-2022-event-301487919.html
SOURCE 10x Genomics, Inc.